Abstract
Background: The current standard of care for breast cancer patients with a positive sentinel lymph node (SLN) is completion axillary lymph node dissection (cALND). Actually there is some controversy about the pertinence of ALND when SLN positive because the risk of axillary recurrence is low. However, the impact on long term survival of not performing ALND on SLN positive patients is not clear. One Step Nucleic Acid Amplification (OSNA®) is an established molecular diagnostic assay, based on the quantitative measurement of Cytokeratin 19 (CK19) mRNA in the whole SLN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
